| Title |
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, September 2018
|
| DOI | 10.2147/tcrm.s146309 |
| Pubmed ID | |
| Authors |
Matthew H Forsberg, Amritava Das, Krishanu Saha, Christian M Capitini |
| Abstract |
Recent advancements in immunooncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 83% |
| Spain | 1 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Scientists | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 87 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 17% |
| Student > Bachelor | 11 | 13% |
| Student > Ph. D. Student | 11 | 13% |
| Researcher | 7 | 8% |
| Other | 5 | 6% |
| Other | 8 | 9% |
| Unknown | 30 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 18 | 21% |
| Medicine and Dentistry | 11 | 13% |
| Immunology and Microbiology | 8 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 8 | 9% |
| Unknown | 32 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2022.
All research outputs
#1,693,570
of 25,385,509 outputs
Outputs from Therapeutics and Clinical Risk Management
#67
of 1,323 outputs
Outputs of similar age
#34,985
of 345,739 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#2
of 39 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,739 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.